🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

7,387 results for “Le” Clear

  1. Cimzia 200 mg solution for injection in pre-filled syringe, SODIUM CHLORIDE

    Pari Pharma GmbH

    Adult women with recurrent implantation failures (RIF)

    phase 3 small molecule active

    1 trial

  2. Cisplatin 1 mg/ml Concentrate for Solution for Infusion, Capecitabine Accord 500 mg film-coated tablets, Inflectra 100 mg powder for concentrate for solution for infusion, IMFINZI 50 mg/mL concentrate for solution for infusion., The Placebo is formulated as 26 mM histidine/histidine-HCl, 275 mM trehalose dihydrate, 0.02% (w/v) polysorbate 80, pH 6.0., Fluorouracil Injection, 50 mg/ml, solution for injection, Mycophenolate Mofetil Accord 250 mg capsules, Capecitabine Accord 150 mg film-coated tablets

    AstraZeneca AB

    Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma

    phase 3 small molecule active

    1 trial

  3. Cisplatin Hikma 1 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Zipalertinib, Carboplatin Hikma 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Pemetrexed Fresenius Kabi 100 mg powder for concentrate for solution for infusion

    Taiho Pharma Netherlands B.V.

    Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations

    phase 3 small molecule active

    1 trial

  4. Cladribine (MAVENCLAD®)

    United Therapeutics Europe Ltd

    Advanced Multiple Sclerosis

    phase 3 small molecule active

    1 trial

  5. Clamp-Crushing technique

    The First People's Hospital of Lianyungang

    Hepatobiliary Disease

    phase 3 other completed

    1 trial

  6. Clemizole HCl

    Harmony Biosciences Holdings

    Dravet Syndrome

    phase 3 small molecule active

    1 trial

  7. Clemizole HCl

    Harmony Biosciences Holdings

    Lennox Gastaut Syndrome

    phase 3 small molecule active

    1 trial

  8. Clesrovimab

    Merck KGaA, Darmstadt, Germany

    Respiratory Syncytial Virus Infection

    phase 3 mab completed

    1 trial

  9. Clifutinib

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Leukemia, Acute Myeloid (AML)

    phase 3 small molecule active

    1 trial

  10. Clinical study to compare the therapeutic effects of two ointments with active substances betamethasone dipropionate and salicylic acid and of one ointment without active substances for patients with chronic stable plaque poriasis

    Alphapharm Pty Ltd

    Chronic stable plaque psoriasis

    phase 3 other active

    1 trial

  11. Clonidine HCl Mucoadhesive Buccal Tablet

    Monopar Therapeutics

    Chemoradiotherapy-Induced Severe Oral Mucositis

    phase 3 small molecule terminated

    1 trial

  12. Co-Trimoxazole 960Mg Dispersible Tablet

    United Therapeutics Europe Ltd

    Spontaneous Bacterial Peritonitis

    phase 3 small molecule active

    1 trial

  13. Cohort 1: Lubiprostone Capsule, Fasted

    Takeda

    Healthy Volunteers

    phase 3 small molecule completed

    1 trial

  14. Cold Stored Platelets

    United Therapeutics Europe Ltd

    Acute Blood Loss

    phase 3 mab completed

    1 trial

  15. Commercially available 0,9 % sterile saline solution with marketing authorization will be utilized as the placebo., KEYTRUDA 25 mg/mL concentrate for solution for infusion, INBRX-106, INBRX-106

    Inhibrx Biosciences

    Head and Neck Squamous Cell Carcinoma

    phase 3 small molecule active

    1 trial

  16. Compound Realgar-Indigo Naturalis Formula Plus Retinoic Acid

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Acute Promyelocytic Leukaemia

    phase 3 small molecule active

    1 trial

  17. Conjunctival Provocation Test Grass-Mix LETI 30 HEP/ml, Conjunctival Provocation Test Olea europaea LETI 30 HEP/ml, Depigoid DUO Grass-Mix/Olea (1000 DPP/ml + 1000 DPP/ml), PLACEBO (Depigoid): the placebo is the solvent used in the investigational medicinal products’ (IMP) formulation. The resulting product is a suspension.

    Lacuna Pharma Pty Ltd

    Allergic rhinoconjunctivitis with or without asthma due to clinically relevant sensitisation to grass and olive pollen.

    phase 3 small molecule active

    1 trial

  18. Continuous Gastrocnemius plane block with ropivacaine

    The First People's Hospital of Lianyungang

    Foot Ankle Injuries

    phase 3 small molecule active

    1 trial

  19. Conventional medical treatment

    Lxo Ireland Designated Activity Company

    Coronary Atherosclerosis and Other Heart Disease

    phase 3 small molecule completed

    1 trial

  20. Copiktra 25 mg hard capsules, Copiktra 15 mg hard capsules, DUVELISIB , BENDAMUSTINE , GEMCITABINE

    Secura Bio Limited

    relapsed/refractory nodal T cell lymphoma with T follicular helper (TFH) phenotype, relapsed/refractory nodal T cell lymphoma with T follicular helper (TFH) phenotype

    phase 3 small molecule active

    1 trial

  21. Cretostimogene Grenadenorepvec

    CG Oncology

    Non Muscle Invasive Bladder Cancer

    phase 3 mab active

    2 trials

  22. Crinecerfont placebo for oral solution, NBI-74788, NBI-74788, Crinecerfont placebo for oral Capsules

    NEUROCRINE BIOSCIENCES INC

    Classic Congenital Adrenal Hyperplasia (CAH)

    phase 3 small molecule active

    1 trial

  23. Cryo-Touch II

    Pacira Ireland Limited

    Facial Wrinkles

    phase 3 other completed

    2 trials

  24. Cryo-Touch III

    Pacira Ireland Limited

    Facial Wrinkles

    phase 3 other completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources